Iacovos P. Michael
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Iacovos P. Michael has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Adam S. Komorowski
Division of Infectious Diseases, Dept. of Medicine, McMaster University, Hamilton, ON, Canada; Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada; Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, ON, Canada
1 shared publication - Alisha E. Sharma
Department of Medicine, University of Toronto, Toronto, ON M5S 3H2, Canada
1 shared publication - Anjali Sachdeva
Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada
1 shared publication - Husam Abdel-Qadir
Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON M5T 3M6, Canada
1 shared publication - Isabella Kojundzic
Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada
1 shared publication - Kairavi Desai
Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON L8P 1H6, Canada
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
The Impact of Beta Blockers on Survival in Cancer Patients: A Systematic Review and Meta-Analysis
Background/Objectives: Beta adrenergic signaling has been implicated in cancer progression, leading to interest in repurposing beta blockers (BBs) as adjunctive anti-cancer agents. However, clinical findings are inconsistent. This systematic review and meta-analysis evaluates the association between BB use and survival outcomes in cancer patients. Methods: A systematic search of OVID Medline, EMBASE, and CENTRAL was conducted through 13 September 2023, for studies comparing survival outcomes in solid tumor patients using BBs versus non-users. Eligible studies reported hazard ratios (HRs) for overall survival (OS), progression-free survival (PFS), or cancer-specific survival (CSS). Perioperative studies and those without BB-specific HRs were excluded. Data extraction and quality assessment were performed in duplicate using ROBINS-I. A random-effects model was used, with heterogeneity assessed by the I2 statistic. Results: Seventy-nine studies (492,381 patients) met the inclusion criteria; 2.5% were prospective. The most frequently studied cancers were breast (n = 33), ovarian (n = 30), and colorectal (n = 28). BB use was associated with improved PFS (HR 0.78, 95% CI: 0.66–0.92, I2 = 79.8%), with significance maintained after excluding high-bias studies (HR 0.74, 95% CI: 0.61–0.91, I2 = 36.6%). No significant associations were observed for OS (HR 0.99, 95% CI: 0.94–1.04, I2 = 84.9%) or CSS (HR 0.95, 95% CI: 0.91–1.00, I2 = 77.4%). Conclusions: BB use may be associated with longer PFS in cancer patients, but findings are limited by study design and heterogeneity; high-quality prospective studies are needed.
Top Cited PapersOpen AccessThe Impact of Beta Blockers on Survival in Cancer Patients: A Systematic Review and Meta-Analysis
Background/Objectives: Beta adrenergic signaling has been implicated in cancer progression, leading to interest in repurposing beta blockers (BBs) as adjunctive anti-cancer agents. However, clinical findings are inconsistent. This systematic review and meta-analysis evaluates the association between BB use and survival outcomes in cancer patients. Methods: A systematic search of OVID Medline, EMBASE, and CENTRAL was conducted through 13 September 2023, for studies comparing survival outcomes in solid tumor patients using BBs versus non-users. Eligible studies reported hazard ratios (HRs) for overall survival (OS), progression-free survival (PFS), or cancer-specific survival (CSS). Perioperative studies and those without BB-specific HRs were excluded. Data extraction and quality assessment were performed in duplicate using ROBINS-I. A random-effects model was used, with heterogeneity assessed by the I2 statistic. Results: Seventy-nine studies (492,381 patients) met the inclusion criteria; 2.5% were prospective. The most frequently studied cancers were breast (n = 33), ovarian (n = 30), and colorectal (n = 28). BB use was associated with improved PFS (HR 0.78, 95% CI: 0.66–0.92, I2 = 79.8%), with significance maintained after excluding high-bias studies (HR 0.74, 95% CI: 0.61–0.91, I2 = 36.6%). No significant associations were observed for OS (HR 0.99, 95% CI: 0.94–1.04, I2 = 84.9%) or CSS (HR 0.95, 95% CI: 0.91–1.00, I2 = 77.4%). Conclusions: BB use may be associated with longer PFS in cancer patients, but findings are limited by study design and heterogeneity; high-quality prospective studies are needed.
- 27 June 2024
- Published by Springer Nature
- Vol. 2810, 123-135
A Versatile Method for Inducible Protein Production in 293 Cells Using the PiggyBac Transposon System
The production of recombinant proteins has helped in understanding of their function and developing new therapies. However, one of the major bottlenecks for protein production is the establishment of reliable mammalian cell lines with high expression levels. In this chapter, we describe a simple and robust system that allows for the quick establishment of stable transgenic 293 cell lines with reproducible and high protein expression levels. This methodology is based on the piggyBac transposon system and enables the inducible production of the protein of interest. Finally, this methodology can easily be used in conventional laboratory cell culture settings without requiring specialized devices.
- 27 June 2024
- Published by Springer Nature
- Vol. 2810, 123-135
A Versatile Method for Inducible Protein Production in 293 Cells Using the PiggyBac Transposon System
The production of recombinant proteins has helped in understanding of their function and developing new therapies. However, one of the major bottlenecks for protein production is the establishment of reliable mammalian cell lines with high expression levels. In this chapter, we describe a simple and robust system that allows for the quick establishment of stable transgenic 293 cell lines with reproducible and high protein expression levels. This methodology is based on the piggyBac transposon system and enables the inducible production of the protein of interest. Finally, this methodology can easily be used in conventional laboratory cell culture settings without requiring specialized devices.